Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Published:2020-02-01 Issue:2 Volume:22 Page:85-95
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Garg Satish K.¹,Wernicke-Panten Karin²,Wardecki Marek³,Kramer Daniel²,Delalande Francois⁴,Franek Edward⁵,Sadeharju Karita⁶,Monchamp Travis⁷,Mukherjee Bhaswati⁸,Shah Viral N.¹

Affiliation:

1. Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

2. Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.

3. Sanofi, Warszawa, Poland.

4. Ividata, Paris, France.

5. Mossakowski Clinical Research Centre, Polish Academy of Sciences, and CSK MSWiA, Warszawa, Poland.

6. Terveystalo Seinäjoki, Seinäjoki, Finland.

7. Endocrinology Services Northwest, Bend, Oregon.

8. Sanofi, Paris, France.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/dia.2019.0382

Reference11 articles.

1. Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

2. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

3. 8. Pharmacologic Approaches to Glycemic Treatment

4. Defining and Reporting Hypoglycemia in Diabetes

5. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial;Journal of Diabetes Science and Technology;2024-02-29

2. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial;Diabetes, Obesity and Metabolism;2023-10-25

3. The use of biosimilar insulins in 2023;Canadian Diabetes & Endocrinology Today;2023-03-20

4. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study;BioDrugs;2022-09-17

5. Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial;Current Medical Research and Opinion;2022-07-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3